News Sentiment

TCRT sentiment intelligence

Alaunos Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.05 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

77/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.0% over one week, -4.7% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Price to earnings forward of Alaunos Therapeutics, Inc. – NASDAQ:TCRT

Market Reaction

Balanced read

47/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 77/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend inactive -4.7% over four weeks
Fair value -73.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 29
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 9
TradingView 8
Stock Titan 7
Market source 6
Investing.com UK 2
GlobeNewswire 2
simplywall.st 2
dars.gov.et 1

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 17
Guidance 2
Regulatory and legal 1
Deals and strategy 1
Analyst action 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-47 of 47
Stock Titan Direct company coverage

ALN1003 obesity data and cash runway update from Alaunos (NASDAQ: TCRT)

Alaunos Therapeutics (NASDAQ: TCRT) announced positive preclinical data for ALN1003, their oral, non-hormonal small-molecule candidate for obesity and metabolic disorders, showing weight loss and improved metabolic markers in mouse studies. Despite promising results, the company

Tone
Neutral 50/100
Event
Earnings
Published
26 May 2026 15:09
Source
Stock Titan
Stocktwits Direct company coverage

Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results

Alaunos Therapeutics announced positive preclinical data for its obesity drug candidate, ALN1003, showing improvements in weight, body composition, insulin sensitivity, and liver health in mouse studies. The oral treatment aims to address obesity and metabolic disorders without h

Tone
Neutral 50/100
Event
Earnings
Published
26 May 2026 15:09
Source
Stocktwits
Investing.com UK Direct company coverage

Alaunos reports preclinical data for obesity drug candidate ALN1003

Alaunos Therapeutics released preclinical data for its oral obesity drug candidate, ALN1003, showing significant body weight reduction and improved metabolic markers in diet-induced obesity mouse studies. Despite positive preclinical results, the company faces financial challenge

Tone
Negative 38/100
Event
Earnings
Published
26 May 2026 15:09
Source
Investing.com UK